MAY 29, 2023 | COMPANY | NEWS

Introducing our new logo and brand identity: reflecting Nonacus' clinical vision for advanced liquid biopsy testing


As we continue to drive innovation in the field, we have honed our focus towards decentralised and cost-effective cancer genomics through our state-of-the-art liquid biopsy testing platform. This rebranding effort signifies our commitment to advancing clinical solutions that revolutionize cancer diagnostics and treatment.

Nonacus_Logo brandline (1)

Our new branding has been meticulously designed to align with our new clinical vision. We aimed to create a modern and impactful identity that resonates with our audience and reflects our dedication to cutting-edge technology in healthcare.

The refreshed colour palette, 'tech blue' and 'healthcare green', represent the two sides of Nonacus' offering: green for GALEAS®, Nonacus' newly launched cloud-based bioinformatics solution, and blue for Cell3™ Target, our proprietary target enrichment technology that underpins all of our tests.

A gradient effect has been introduced for the first time in our brand identity, emphasizing the seamless integration of these concepts. This gradient effect underscores the close relationship between our bioinformatics solution and target enrichment technology, forming a cohesive and unified visual identity. It signifies our commitment to providing a comprehensive and holistic approach to cancer genomics.

In our rebranding efforts, we have selected a single typeface that will be used consistently across all communications. This choice ensures that our brand is distinctly recognizable and allows for a cohesive visual experience. By employing this typeface in both the body font and the logo, we reinforce our commitment to delivering clear and consistent messaging.


“These changes not only reflect our clinical vision for advanced liquid biopsy testing but also signify our dedication to revolutionizing cancer genomics. Our clean lines, vibrant colors, and unified visual elements demonstrate our commitment to delivering innovative solutions that empower healthcare professionals and improve patient outcomes” Paula Miquel, Head of Marketing at Nonacus.


We are excited to embark on this new chapter and invite you to join us on our journey towards a future where cancer genomics becomes more accessible, efficient, and effective than ever before. Stay tuned for more updates on our revolutionary advancements in the field of cancer diagnostics and treatment.


Categories: Company and News.